Peptide-T

DB19279InvestigationalSmall molecule

Peptide-T is under investigation in clinical trial NCT00000392 (Phase II Study of the Efficacy of Peptide T in Hiv-positive Individuals With Cognitive Impairment.).

Mechanism: Pharmacologically active on C-C chemokine receptor type 5 and T-cell surface glycoprotein CD4
Curator reviewed
Formula / weight: C₃₅H₅₅N₉O₁₆ · 857.872 g/mol (avg)
Also known as: L-threonine, l-alanyl-l-seryl-l-threonyl-l-threonyl-l- threonyl-l-asparaginyl-l-tyrosyl- · Peptide T

Resolves to

Compound

UNII05DYM3ZS1XCAS106362-32-7ChEMBLCHEMBL180971

Clinical / RWD

RxNorm2644766

Structure

InChIKeyIWHCAJPPWOMXNW-LYKMMFCUSA-NSMILES

C[C@@H](O)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(O)=O

Targets

P51681CCR5P01730CD4

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1Marketed productAcross 1 country and 1 labeller

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Peptide-T, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account